To read the full story, subscribe or sign in.

Japan’s Aculys Pharma raises $60M in series A for sleep disorder candidate

Nov. 2, 2021

Aculys Pharma Inc. closed its $60 million series A financing round, with the funds to be used to develop pitolisant (Wakix), a selective histamine H3 receptor antagonist/inverse agonist, in Japan.

BioWorld Asia Financings Neurology/psychiatric Series A Japan

Today's news in brief

BioWorld

BioWorld briefs for April 14, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for April 14, 2025.

Antibodies binding to spike proteins on the surface of SARS-CoV-2 virus

Australian researchers discover new compound to treat long COVID

BioWorld

Researchers have developed a new compound that can prevent long COVID symptoms in mice that could lead to a future drug for the debilitating condition in humans....

Caution tape displaying US flag, tariffs

Biopharma exempt from US reciprocal tariffs, but not untouched

BioWorld

At first glance, it appears that biopharmaceuticals dodged the latest U.S. tariff bullet; med-tech, not so much. According to the executive order President Donald...

FDA wants a shift away from animal testing

BioWorld MedTech

In a roadmap to change animal testing requirements for INDs, the U.S. FDA said its new approach will improve drug safety, hasten the evaluation process, and lower...